Multi-modal cancer therapy using viral hitch-hiking

The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the pr...

Full description

Saved in:
Bibliographic Details
Main Authors Schirrmacher, Volker, Beckhove, Philipp, Fournier, Philippe, Aigner, Maximilian
Format Patent
LanguageEnglish
Published 27.03.2012
Online AccessGet full text

Cover

Abstract The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.
AbstractList The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.
Author Beckhove, Philipp
Schirrmacher, Volker
Aigner, Maximilian
Fournier, Philippe
Author_xml – sequence: 1
  givenname: Volker
  surname: Schirrmacher
  fullname: Schirrmacher, Volker
– sequence: 2
  givenname: Philipp
  surname: Beckhove
  fullname: Beckhove, Philipp
– sequence: 3
  givenname: Philippe
  surname: Fournier
  fullname: Fournier, Philippe
– sequence: 4
  givenname: Maximilian
  surname: Aigner
  fullname: Aigner, Maximilian
BookMark eNrjYmDJy89L5WQw9i3NKcnUzc1PScxRSE7MS04tUijJSC1KLKhUKC3OzEtXKMssAkplZJYkZ-hmZGYDhXgYWNMSc4pTeaE0N4OCm2uIs4duaXFBYklqXklxfHpRIogysDA0MTK3NDQmQgkAx2EvDw
ContentType Patent
CorporateAuthor Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
CorporateAuthor_xml – name: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
DBID EFH
DatabaseName USPTO Issued Patents
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EFH
  name: USPTO Issued Patents
  url: http://www.uspto.gov/patft/index.html
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
ExternalDocumentID 08142791
GroupedDBID EFH
ID FETCH-uspatents_grants_081427913
IEDL.DBID EFH
IngestDate Sun Mar 05 22:33:47 EST 2023
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-uspatents_grants_081427913
OpenAccessLink https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8142791
ParticipantIDs uspatents_grants_08142791
PatentNumber 8142791
PublicationCentury 2000
PublicationDate 20120327
PublicationDateYYYYMMDD 2012-03-27
PublicationDate_xml – month: 03
  year: 2012
  text: 20120327
  day: 27
PublicationDecade 2010
PublicationYear 2012
References Kenney, 1994, J Natl Cancer Inst 86(16): 1185-6.
Thorne, 2006, Science 311: 1780-1784.
Queen et al. (6180370) 20010100
Lederman et al, Molecular Immunology 28:1171-1181, 1991.
Nagai Y, Kato A, 1999, Microbiol. Immunol. 43: 613-624.
Gotoh, 1988, Virology 163(1): 174-182.
Dela Cruz, 2004, Clin Exp Med 4(2): 57-64.
Conzelmann, 1998, Annu Rev Genet 32: 123-62.
Schirrmacher, 1998, Semin Oncol 25(6): 677-96.
Pritzer, 1990, Virus Res 15(3): 237-242.
Batliwalla, 1998, Mol Med 4(12): 783-94.
Haas, 2006, Int. J. Cancer, 118(3): 658-67.
Köhler and Milstein, Nature 256, 1975, 495.
Schirrmacher V, 2005, Cancer Immunol. Immunother. 54, 587-598.
Moss, 1996, J Naturopathic Med 6(1): 23-32.
Schirrmacher V et al., 1999, Gene Ther. 6, 63-73.
Riemer et al, Mol. Immunol. 42: 1121-1124, 2005.
Csatary, 1999, Anticancer Res 19 (1B)): 635-8.
(1-275-724) 20030100
Cole, 2005, Nature Med 11(10): 1073-1081.
Emergency Preparedness Information eXchange: Foreign Animal Diseases: Newcaste Disease. Burnaby, Canada. Telematics Research Lab, Simon Fraser University, 2002.
Scheid A, Choppin PW, 1977, Virology 80, 54-66.
Bonasio, 2006, Curr Opin Immunol, Aug., 18(4): 503-11.
Damle et al., 1981, PNAS, 5096-5098.
Csatary, 1993, Cancer Detect Prev 17(6): 619-27.
Witte et al, Cancer and Metastasis Reviews 17: 155-161, 1998.
Rooney, 2005, Nature Med 11(10): 1051-1052.
Haas, 2005, Vaccine 23: 2439-2453.
Kirn, 1996, Mol Med Today 2(12): 519-27.
Pecora AL et al., 2002, J. Clin. Oncol. 20, 2251-2266.
Galfré, Meth. Enzymol. 73, 1981, 3.
Lorence, 1994, Cancer Res 54(23): 6017-6021.
Henry et al, Cancer Res. 64: 7995-8001, Nov. 1, 2004.
Roberts, 1998, Virology 20, 247(1): 1-6.
Stancoviski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.
Schirrmacher, 2001, Int J Oncol 18: 945-952.
Reichard, 1992, J Surg Res 52(5): 448-53.
Römer-Oberdörfer A et al., 2003, J. Gen. Virol. 84; 3121-3129.
Lorence, 1994, J Natl Cancer Inst 86(16): 1228-33.
References_xml – year: 20010100
  ident: 6180370
  contributor:
    fullname: Queen et al.
– year: 20030100
  ident: 1-275-724
Score 2.839575
Snippet The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus...
SourceID uspatents
SourceType Open Access Repository
Title Multi-modal cancer therapy using viral hitch-hiking
URI https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8142791
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NSwMxEB1qEdSTomL9Igev0Ww2NulZuiyC0oNCbyXZTT9gu1t2t0j_vTNZKV70mkAyTJiZl_DeBOBBZLmRCMMxxKXiymqFeXAoOULvSFvnTB7aNb29D9NP9Tp9nvYg3Wth1hhGfIO2NI_bZtNWgVyJ6b07eN41f6YegSV1H_gqi8rmk3z-ZCIlNcnYD4wgat84SU_gCJdAyFa2za-ikZzC4SSMnkHPl-cQB60rX1e5LVhGzq5Zp37aMWKfLxjxbQu2XKEj-XJFb9gXwJLxx0vK9zvMFjUxV2bix5L4Evp4g_dXwOZGIfLHRJJ5BEhej2wcOT2iD_GEdcIPYPDnMtf_zN3AMdZvSZQoqW-h39Zbf4c1snX3wQHfi9dxFQ
link.rule.ids 230,309,783,805,888,64374
linkProvider USPTO
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3JTsMwEB1VBbGcQIAoZfGBqyFxTJ2eoVHYqhxA6i2yE3eR0qRKUiH-vjMJqrjA1ZZsa6yZebbfPAPcOknqC4Th6OJCcqmVxDg4EByht6u0MX7ayDW9jwfhp3yZPEw6EG5rYZboRnyFa6nu1tWqLhpyJYb3duN5K_5MGoE5qQ985Vmh0yid3vuuFIrK2HfoKYpU9EdBeAj7OAiCtryufqWN4Ah2o6b1GDo2PwGvqXblyyLVGUvI3CVr65--GfHPZ4wYtxmbL9CUfL6gW-xTYMHo4zHk2xniWUncldj5WYt3Bl08w9tzYFNfIvbHUJJYhEhWDbXnGjWkL_EcbRzbg96fw1z803cDe9FTEL89j1_7cIDJXBA_SqhL6Nbl2l5hwqzNdWOLDUNLdBA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Multi-modal+cancer+therapy+using+viral+hitch-hiking&rft.inventor=Schirrmacher%2C+Volker&rft.inventor=Beckhove%2C+Philipp&rft.inventor=Fournier%2C+Philippe&rft.inventor=Aigner%2C+Maximilian&rft.number=8142791&rft.date=2012-03-27&rft.externalDBID=n%2Fa&rft.externalDocID=08142791